Navigation Links
SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
Date:9/10/2007

TAMPA, Fla.September 10, 2007--Accentia Biopharmaceuticals (NASDAQ: ABPI) announces evidence that most, if not all cases of chronic sinusitis (CS), are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the Companys ongoing pivotal Phase 3 clinical trial for its lead pharmaceutical product, SinuNase, an intranasal formulation of the antifungal amphotericin B 0.01% suspension. In order to be enrolled in the clinical trial, patients must have had well-documented CS based on a history of the requisite symptoms, nasal endoscopy findings, and CT scan demonstrating characteristic mucosal changes in the sinuses. At the time of enrollment, all patients have had nasal mucin collected. Subsequently, these specimens are being tested for eosinophilic major basic protein (eMBP). In the first fifty specimens now analyzed, all have been positive for eMBP, a toxic protein released by inflammatory cells in response to fungi. The Company believes that these findings strongly support a fungal-induced inflammation as the cause of CS.

SinuTest, the diagnostic used to measure eMBP in the nasal mucin, is a patented technology developed at the Mayo Foundation for Medical Education and Research. The technology is exclusively licensed to IMMCO Diagnostics, which has an exclusive commercialization agreement with Accentia Biopharmaceuticals. The Company believes that SinuTest will be a useful adjunct for identification of patients who are suspected of having CS and who may be candidates for treatment with SinuNase, assuming FDA approval.

As previously announced, Accentia has received Fast Track status from the Food and Drug Administration (FDA) for SinuNase, and it is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial with severe CS patients at more than 50 sites across the U.S. To the knowledge of the Company, this is the first and only Phase 3 clinica
'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Farm kids almost twice as likely to die from injury as children overall
9. Chronic pain up almost 40 percent among US workers in past decade
10. Hunger in America rises by 43 percent over last five years
11. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... we thought that gene expression was modulated only by transcription ... could be regulated by the RISC complex (siRNA-mediated degradation via ... level is even more complex than we first imaginated... ... requirement for using a weapon or tool is finding it. ...
... five mammals living on Earth is a bat, yet their ... record and conflicting or incomplete theories about their origins and ... Riverside Biology Professor Mark Springer, has published a paper in ... molecular biology and the fossil data to fill in many ...
... breast cancer treated with radical mastectomy and adjuvant chemotherapy, ... outcomes with few long-term toxic effects, according to a ... the January 19 issue of the Journal of the ... therapy trial was designed to determine the effect on ...
Cached Biology News:A new mechanism of regulating RNA degradation 2A new mechanism of regulating RNA degradation 3Molecular biology fills gaps in knowledge of bat evolution 2Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down 2
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: ... Bar-Gil as an independent director of the Company,s ... of AeroScout and served as its CEO until its ... 2012, a $240 million transaction. Recognized as the inventor ... Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions focused ...
(Date:12/13/2014)... Rockville, Maryland (PRWEB) December 12, 2014 ... Maryland, today announced its new name: Therabron Therapeutics ... words therapy and bronchioles (a type of structure in ... incorporating the company’s mission to develop novel protein therapeutics ... board of directors decided to change the name to ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/12/2014)... InSphero AG, the world’s leading provider of 3D ... data presented recently by Genentech (South San Francisco, CA) ... model system for assessment of liver toxicity. ... Analysis and Screening Technologies (FAST) Congress summarized a ... 3D InSight™ Human Liver Microtissues to 42 known ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
... ... ... ... ...
... ... ... ... ...
... leap forward in the understanding of how specific types of ... of scientists has succeeded in mapping the entire network of ... network, indicating which factors can combine to determine cell fate, ... journal Cell . Transcription factors (TFs) are proteins ...
Cached Biology Technology:LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 2LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 3LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 4LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 5China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 2China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 3China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 4China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 5China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 6China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 7China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 8China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 9China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 10China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 11China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 12China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 13China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 14China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 15China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 16China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 17China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 18China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 19China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 20China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 21Researchers create atlas of transcription factor combinations 2
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
Biology Products: